H2-Db Inhibitors
The class of H2-Db inhibitors encompasses a range of compounds that modulate the expression and function of H2-Db, a major histocompatibility complex class I protein involved in antigen presentation. Brefeldin A disrupts ER to Golgi transport, indirectly influencing H2-Db by impacting antigen presentation pathways. Proteasome inhibitors such as MG-132 and Lactacystin alter ubiquitin-proteasome-mediated protein degradation, affecting H2-Db expression in the context of antigen processing. Wortmannin, a PI3K inhibitor, indirectly modulates H2-Db by disrupting the PI3K/AKT pathway, altering downstream signaling cascades crucial for antigen presentation. Rapamycin, an mTOR inhibitor, influences H2-Db indirectly by disrupting mTORC1, impacting antigen presentation pathways. Chloroquine disrupts endosomal acidification, modulating H2-Db by influencing pathways involved in presenting antigens found in endocytosed material.
SP600125, a JNK inhibitor, indirectly influences H2-Db by disrupting JNK signaling, affecting pathways related to presenting antigens found in stress-induced processes. Imatinib, through Src family kinase inhibition, modulates H2-Db by altering downstream signaling pathways and cellular processes associated with antigen presentation. Zoledronic Acid inhibits farnesyl diphosphate synthase, indirectly impacting H2-Db expression by affecting antigen presentation pathways related to prenylated proteins. Oxytetracycline disrupts lysosomal acidification, influencing H2-Db by modulating lysosomal pathways involved in antigen processing. Ionomycin induces calcium influx, indirectly modulating H2-Db by activating calcium-dependent signaling pathways crucial for antigen presentation. This diverse class of inhibitors provides valuable insights into the intricate mechanisms governing H2-Db expression and function, shedding light on avenues for further research in antigen presentation and immune response regulation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Disrupts the ER to Golgi transport, indirectly modulating H2-Db. Brefeldin A inhibits the activation of ARF GTPases, leading to the disassembly of COPI-coated vesicles. This disruption impacts antigen presentation pathways, influencing H2-Db expression and function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
Proteasome inhibitor indirectly affecting H2-Db. MG-132 disrupts proteasome function, altering the degradation of ubiquitinated proteins. This modulation impacts antigen processing pathways, influencing H2-Db expression and function in the context of antigen presentation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3K inhibitor indirectly influencing H2-Db. Wortmannin disrupts the PI3K/AKT pathway, altering downstream signaling cascades that impact antigen presentation pathways. This modulation can influence H2-Db expression and function in the context of antigen processing and presentation. | ||||||
2-D08 | 144707-18-6 | sc-507405 | 5 mg | $150.00 | ||
Disrupts autophagy, indirectly modulating H2-Db. 2-D08 inhibits ULK1, a key autophagy initiation kinase. This disruption impacts autophagy-mediated antigen presentation pathways, influencing H2-Db expression and function in the context of presenting intracellular antigens. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor influencing H2-Db indirectly. Rapamycin disrupts mTORC1 complex, altering downstream signaling cascades that impact antigen presentation pathways. This modulation can influence H2-Db expression and function in the context of antigen processing and presentation. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
Proteasome inhibitor indirectly affecting H2-Db. Lactacystin disrupts proteasome function, altering the degradation of ubiquitinated proteins. This modulation impacts antigen processing pathways, influencing H2-Db expression and function in the context of antigen presentation. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Disrupts endosomal acidification, indirectly modulating H2-Db. Chloroquine inhibits lysosomal enzymes, impacting endosomal pathways involved in antigen processing. This modulation influences H2-Db expression and function in the context of presenting peptides found in endocytosed antigens. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor indirectly influencing H2-Db. SP600125 disrupts JNK signaling, affecting downstream signaling cascades that impact antigen presentation pathways. This modulation can influence H2-Db expression and function in the context of presenting antigens found in stress-induced pathways. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Affects H2-Db indirectly through Src family kinase inhibition. Imatinib disrupts downstream signaling pathways, altering cellular processes related to antigen presentation. This modulation can influence H2-Db expression and function in the context of presenting antigens found in pathways involving Src family kinases. | ||||||
Zoledronic acid, anhydrous | 118072-93-8 | sc-364663 sc-364663A | 25 mg 100 mg | $90.00 $251.00 | 5 | |
Inhibits farnesyl diphosphate synthase, indirectly modulating H2-Db. Zoledronic Acid disrupts the mevalonate pathway, impacting protein prenylation. This modulation influences antigen presentation pathways, affecting H2-Db expression and function in the context of presenting antigens found in prenylated proteins. | ||||||